摘要
目的观察长春瑞滨联合奈达铂治疗中晚期食管癌的有效性及安全性。方法全组共35例，其中男性22例，女性13例；年龄39～77岁，中位年龄53岁；鳞癌29例，腺癌6例；初治8例，复治27例，复治患者均应用过一个及一个以上化疗方案，入组后给予长春瑞滨注射液25mg／m^2，加入0．9％氯化钠注射液100ml中，快速静脉滴注半小时，第1、5天；奈达铂注射液，80mg／m^2，加入0．9%氯化钠注射液500ml中，缓慢静脉滴注2小时，第1天。每4周重复。2周期后按WHO标准评价近期疗效和毒性反应。结果全组共接受了137周期治疗，每例1～6周期，平均3．8周期，均可评价疗效及毒副作用。获得1例CR（2．9％），12例PR（34．3％）。初治或复治、分期、病理类型对近期疗效均无影响。常见毒性反应为骨髓抑制。结论长春瑞滨联合奈达铂治疗中晚期食道癌有较好的确切疗效，并且毒性反应可以控制，值得临床推广使用。
Objective To evaluate the efficacy and toxicity of nedaplatin combined with vinorelbine in Treating Advanced Esophageal Carcinoma. Methods Thirty five patients with Advanced Esophageal Carcinoma were treated with nedaplatin 80 mg/m^2 on days Ⅰ and vinoreibine 25 mg/m^2 on days 1 and 5 delivered by venous injection. The regimen was repeated more than 2 cycles. WHO crieerias were used to evaluation. Results Gross efficiency rate was 37. 1% with 1 cases CR and 12 cases PR. The median TTP was 5. 1 months. Toxic effects can be controlled. Conclusion Nedaplatin combined with vinorelbine in Treating Advanced Esophageal Carcinoma had better effective and less toxic effects.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2008年第10期734-736,共3页
Cancer Research on Prevention and Treatment
关键词
长春瑞滨
奈达铂
晚期食管癌
治疗
Vinorelbine
Nedaplatin
Advanced Esophageal Carcinoma
Treatment
